Paper Dated: November 17, 2008

In Reply to USPTO Correspondence of July 16, 2008

Attorney Docket No. 0115-061069

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims

Claim 1 (Currently Amended): A compound according to formula I

$$P_1$$
 P_2 P_3 P_4 P_4 P_5 P_6 P_8 P_8

wherein

P represents -N<,

(X)_n represents –OOC-, -COO-, -CONH-, -CH=N-; -CH=N-,

 R_a represents H, lower alkyl, -OR₃, -O (CO) R₃, -O (CO) OR₃, -O (CO) NR₃R₄, -N₃R₄, -NR₃ (CO) R₄, -COOR₃, -CONR₃R₄, -CH=CHCOOR₃, -CF₃, -CN, -NO₂, SO₃H, PO₃H or halogen,

wherein

R₃ and R₄ represent H or lower alkyl,

R_b represents H, OH, -OSO₂Me, -OSO₂W

wherein

W represents optionally substituted aryl or heteroaryl, -OCO(CHOH)₂COOR₅ wherein

 R_5 represents H or lower alkyl; or represents the formula -Sp₃-R₆, wherein

Sp₃ represents a covalent bond, -O-, -OCH₂-, -OSO₂CH₂-, -OSO₂-, -OSO₂- (p) C₆H₄O- and

R₆ represents one of carbohydrate structures A-D:

Paper Dated: November 17, 2008

In Reply to USPTO Correspondence of July 16, 2008

Attorney Docket No. 0115-061069

$$R_{7}O_{11}OR_{9}OR_{10}OR_{7}OR_{10}OR_{7}OR_{8}OR_{8}OR_{8}OR_{12}OR_{13}OR_{7}OR_{14}OR_{9}OR_{14}OR_{$$

wherein

R₇, R₈, R₉, R₁₁, R₁₂, R₁₃ and R₁₄ represent independently of each other H, lower alkyl, aryl(lower alkyl), -CO-lower alkyl, -CO-aryl, -SO₃ or -PO₃,

 R_{10} represents -CH₂OR₁₆ or -COOR₁₇, and

R₁₅ represents -CH₂OR₁₆, -COOR₁₇, -CH₂NH₂, -CH₂OPO₃ or -CH₂OSO₃,

wherein

R₁₆ and R₁₇ independently of each other represent H, lower alkyl, aryl (lower alkyl), -CO-lower alkyl, -CO-aryl, -SO₃ or -PO₃,

Z represents optionally substituted aryl or heteroaryl,

Sp₁ represents lower alkyl group -(CH₂)_p-, wherein p is from 2-6, which is unsubstituted, mono or poly-substituted by -OH, -OR₁₈, halogen or cyano group, wherein one or more -CH₂- groups may independently be replaced by -O-, -CO-, -CO-O-, -O-CO-, -NR₁₉-, -NR₁₉-CO-, -CO-NR₁₉-, -CH=CH-, -C \equiv C- -and wherein R₁₈ and R₁₉ represent a hydrogen atom or lower-alkyl; <u>alkyl</u>,

Sp₂ represents a covalent bond or a lower alkyl group -(CH₂)_q-, wherein q is from 1-6, which

Paper Dated: November 17, 2008

In Reply to USPTO Correspondence of July 16, 2008

Attorney Docket No. 0115-061069

is unsubstituted, mono or poly-substituted by -OH, -OR₂₀, halogen or cyano group, wherein one or more -CH₂- groups may independently be replaced by -O-, -CO-, -CO-, -CO-, -NR₂₁-, -NR₂₁-CO-, -CO-NR₂₁-, -CH=CH-, -C= \mathbb{C} - and wherein R₂₀, and R₂₁, represents a hydrogen atom or lower-alkyl; alkyl,

Y represents optionally substituted aryl or heteroaryl.

Claims 2-6 (Cancelled).

Claim 7 (Currently Amended): A compound according to claim 1 having the formula IVa

$$P_{1,...}$$
 P_{2} P_{2} P_{2} P_{2} P_{3} P_{4} P_{4}

IvaIVa

wherein P is -N= and $(X)_n$ is -OOC-, -COO-, -CONH, -CH=N-, and R_a , R_b , Sp_1 , Sp_2 , Y, Z and n are as defined in claim 1.

Claim 8 (Previously Presented): A compound according to claim 1 having the formula IVb,

$$R_{22}$$
 $SP_{1,...}$
 R_{a}
 R_{21}

IVb

wherein P is -N= and $(X)_n$ is -OOC-, -COO-, -CONH, -CH=N-, and

R_a, R_b, Sp₁, are as defined hereinabove and wherein R₂₁ and R₂₂ represent H, lower alkyl, lower PP6867.DOC Page 4 of 14

Paper Dated: November 17, 2008

In Reply to USPTO Correspondence of July 16, 2008

Attorney Docket No. 0115-061069

alkoxy or halogen.

Claims 9-12 (Cancelled).

Claim 13 (Previously Presented): A pharmaceutical composition comprising a

therapeutically effective amount of a compound of claim 1 with a pharmaceutically acceptable

carrier.

Claim 14 (Currently Amended): A pharmaceutical composition according to

claim 13 for the treatment or prevention of arteriosclerosis or for the reduction of cholesterol

levels.

Claim 15 (Currently Amended): A kit comprising a pharmaceutical composition

according to claim 13 for use in the treatment or prevention of arteriosclerosis or for the

reduction of cholesterol levels.

Claim 16 (Currently Amended): A method for the treatment or prevention of

arteriosclerosis or for the reduction of cholesterol levels comprising administering to a subject in

need of such treatment an effective amount of a compound according to claim 1.

Claim 17 (Cancelled).

Page 5 of 14

Paper Dated: November 17, 2008

In Reply to USPTO Correspondence of July 16, 2008

Attorney Docket No. 0115-061069

Claim 18 (Currently Amended): A compound according to claim 1 having the formula IIIa or formula IIId

IIId

wherein,

R_a represents H straight chain or branched C(1-8)alkyl, -OR₃, -NR₃R₄, -COOR₃,
-CONR₃R₄, -CH=CHCOOR₃, -CF₃, -CN, -NO₂, SO₃H, PO₃H or halogen, wherein R₃
and R₄ represent independently of each other H or straight chain or branched
C(1-8)alkyl,

R_b represents H, OH, -OSO₂Me, -OSO₂W wherein W represents optionally substituted aryl or heteroaryl, OCO(CHOH)₂COOR₅ wherein R₅ represents H or straight chain or branched C(1-8)alkyl; or represents the formula –Sp₃- R₆,

wherein

Sp₃ represents a covalent bond, -O-, -OCH₂-, -OSO₂CH₂-, -OSO₂-(p)C₆H₄O- and R₆ represents one of carbohydrate structures A-D:

Paper Dated: November 17, 2008

In Reply to USPTO Correspondence of July 16, 2008

Attorney Docket No. 0115-061069

$$R_7O_{10}$$
 OR_8 OR_11 OR_7 OR_8 OR_9 O

wherein,

R₇, R₈, R₉, R₁₁, R₁₂, R₁₃ and R₁₄ represent independently of each other H, straight chain or branched C(1-8)alkyl, aryl(C(1-8)alkyl), -CO- (C(1-8)alkyl), -CO-aryl, -SO₃- or -PO₃-,

 R_{10} represents -CH2OR16 or -COOR17, and

 R_{15} represents -CH₂OR₁₆, COOR₁₇, -CH₂NH₂-, CH₂OPO₃- or -CH₂OSO₃-, wherein

 R_{16} and R_{17} independently of each other represents H, straight chain or branched C(1-8)alkyl, aryl (C(1-8)alkyl), -CO-(C(1-8)alkyl), -CO-aryl, $-SO_3-$ or $-PO_3-$,

- Z represents optionally substituted aryl,
- sp₁ represents a straight chain or branched alkyl group -(CH₂)_p-, wherein p is from 2-6, which is unsubstituted, mono or poly-substituted by -OH, -OR₁₈, halogen or cyano group, wherein one or more -CH₂- groups may independently be replaced by -O-, -CO-, -CO-O-, -O-CO-, -NR₁₉-, -NR₁₉-CO-, -CO-NR₁₉-, -CH=CH-, -C≡C-, -and wherein R₁₈ and R₁₉ represent a hydrogen atom or straight chain or branched $\frac{C(1-8)alkyl}{C(1-8)alkyl}$,

Sp₂ represents a covalent-bond; bond,

Y represents optionally substituted aryl.

Paper Dated: November 17, 2008

In Reply to USPTO Correspondence of July 16, 2008

Attorney Docket No. 0115-061069

Claim 19 (Previously Presented): A compound according to claim 18 wherein R_a is in the meta-position and R_b is in the para-position.

Claim 20 (Currently Amended): A compound according to—clam 18 claim 18 wherein R_a is H, straight chain or branched C(1-8)alkyl, -OR₃, -NR₃R₄, -COOR₃, -CONR₃R₄ or halogen, wherein R₃ and R₄ represent independently of each other H or straight chain or branched C(1-8)alkyl.

Claim 21 (Previously Presented): A compound according to claim 18 wherein R_b is H, OH, -OSO₂Me, OSO₂Ph; or the formula -Sp₃-R₆, wherein Sp₃, preferably represents a covalent bond, -O-, -OCH₂- or -OSO₂CH₂- and R₆ represents one of carbohydrate structures A-D, preferably carbohydrate structures A, B or D.

Claim 22 (Currently Amended): A compound according to claim 18 wherein $\mathrm{Sp_1}$ represents a lower alkyl $-\mathrm{CH_2}$)_m- group, which is unsubstituted, mono or poly-substituted by -OH, -OR₁₈, halogen or cyano group, wherein R₁₈ represents hydrogen or straight chain or branched C(1-8) alkyl and m is 1 to 3.

Claim 23 (Previously Presented): A compound according to claim 18 wherein Y represents an optionally substituted phenyl group.

Claim 24 (Previously Presented): A compound according to claim 18 wherein Z represents an optionally substituted phenyl group.

Claim 25 (Previously Presented): A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 18 with a pharmaceutically acceptable carrier.

Paper Dated: November 17, 2008

In Reply to USPTO Correspondence of July 16, 2008

Attorney Docket No. 0115-061069

Claim 26 (Currently Amended): A pharmaceutical composition according to claim 25 for the treatment or prevention of arteriosclerosis or for the reduction of cholesterol levels.

Claim 27 (Currently Amended): A kit comprising a pharmaceutical composition according to claim 25 for use in the treatment or prevention of arteriosclerosis or for the reduction of cholesterol levels.

Claim 28 (Currently Amended): A method for the treatment or prevention of arteriosclerosis or for the reduction of cholesterol levels comprising administering, to a subject in need of such treatment, an effective amount of a compound according to claim 18.